The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2020 | Matching-adjusted indirect comparisons of acalabrutinib vs ibrutinib in treatment-naïve CLL
Matthew Davids, MD, of the Dana-Farber Cancer Institute, Boston, MA, outlines data presented at EHA 2020 evaluating matched-adjusted indirect comparisons of efficacy and safety of acalabrutinib versus ibrutinib in treatment-naïve chronic lymphocytic leukemia (CLL) patients based on data collated from the ELEVATE CLL TN study (NCT02475681) as well as the RESONATE-2 study (NCT01722487). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
